{"id":"NCT01061736","sponsor":"Sanofi","briefTitle":"Evaluation of Sarilumab (SAR153191/REGN88) on Top of Methotrexate in Rheumatoid Arthritis Patients","officialTitle":"A Randomized, Double-blind, Placebo-controlled, Multicenter, Two-part, Dose Ranging and Confirmatory Study With an Operationally Seamless Design, Evaluating Efficacy and Safety of SAR153191 on Top of Methotrexate (MTX) in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to MTX Therapy","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2010-03","primaryCompletion":"2013-10","completion":"2013-10","firstPosted":"2010-02-03","resultsPosted":"2017-06-28","lastUpdate":"2017-06-28"},"enrollment":1675,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"DRUG","name":"Sarilumab","otherNames":["SAR153191","REGN88"]},{"type":"DRUG","name":"Placebo (for sarilumab)","otherNames":[]},{"type":"DRUG","name":"Methotrexate","otherNames":[]},{"type":"DRUG","name":"Folic Acid","otherNames":[]}],"arms":[{"label":"Part A: SAR 100 mg qw","type":"EXPERIMENTAL"},{"label":"Part A: SAR 150 mg qw","type":"EXPERIMENTAL"},{"label":"Part A: SAR 100 mg q2w","type":"EXPERIMENTAL"},{"label":"Part A: SAR 150 mg q2w","type":"EXPERIMENTAL"},{"label":"Part A: SAR 200 mg q2w","type":"EXPERIMENTAL"},{"label":"Part A: Placebo qw","type":"PLACEBO_COMPARATOR"},{"label":"Part B Cohort 1: Non-selected Doses","type":"EXPERIMENTAL"},{"label":"Part B: SAR 150 mg q2w (Cohort 1[Selected Dose]+Cohort 2)","type":"EXPERIMENTAL"},{"label":"Part B: SAR 200 mg q2w (Cohort 1[Selected Dose]+Cohort 2)","type":"EXPERIMENTAL"},{"label":"Part B: Placebo q2w (Cohort 1[Selected Dose]+Cohort 2)","type":"EXPERIMENTAL"}],"summary":"Primary Objectives:\n\nPart A (dose ranging study):\n\nTo demonstrate that sarilumab (SAR153191/REGN88) on top of MTX was effective on reduction of signs and symptoms of rheumatoid arthritis at 12 weeks.\n\nPart B (pivotal study):\n\nTo demonstrate that sarilumab added to MTX was effective in:\n\n* reduction of signs and symptoms of rheumatoid arthritis at 24 weeks\n* inhibition of progression of structural damage at 52 weeks\n* improvement in physical function at 16 weeks\n\nSecondary Objectives:\n\nPart B:\n\nTo demonstrate that sarilumab added to MTX was effective in induction of a major clinical response at 52 weeks\n\nTo assess the safety of sarilumab added to MTX\n\nTo document the pharmacokinetic profile of sarilumab added to MTX in participants with active rheumatoid arthritis who were inadequate responders to MTX therapy.","primaryOutcome":{"measure":"Part A: Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 12","timeFrame":"Baseline to Week 12","effectByArm":[{"arm":"Part A: SAR 100 mg qw","deltaMin":62,"sd":null},{"arm":"Part A: SAR 150 mg qw","deltaMin":72,"sd":null},{"arm":"Part A: SAR 100 mg q2w","deltaMin":49,"sd":null},{"arm":"Part A: SAR 150 mg q2w","deltaMin":66.7,"sd":null},{"arm":"Part A: SAR 200 mg q2w","deltaMin":65.4,"sd":null},{"arm":"Part A: Placebo qw","deltaMin":46.2,"sd":null}],"pValues":[{"comp":"OG000 vs OG005","p":"0.1155"},{"comp":"OG001 vs OG005","p":"0.0041"},{"comp":"OG002 vs OG005","p":"0.7119"},{"comp":"OG003 vs OG005","p":"0.0363"},{"comp":"OG004 vs OG005","p":"0.0426"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":6},"locations":{"siteCount":262,"countries":["United States","Argentina","Australia","Austria","Belarus","Belgium","Brazil","Canada","Chile","Colombia","Czechia","Egypt","Estonia","Finland","Germany","Greece","Hungary","India","Lithuania","Malaysia","Mexico","Netherlands","New Zealand","Norway","Philippines","Poland","Portugal","Romania","Russia","South Africa","South Korea","Spain","Taiwan","Thailand","Turkey (TÃ¼rkiye)","Ukraine"]},"refs":{"pmids":["27600829","24297381","25733246","36413080","36008838","34519964","32907617","32522251","32343882","31452928","31004324","27716324"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":50},"commonTop":["Neutropenia","Upper respiratory tract infection","Accidental overdose","Alanine aminotransferase increased","Nasopharyngitis"]}}